MapLight Therapeutics, Inc.
MPLT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001770069
In the last 90 days, MapLight Therapeutics, Inc. insiders filed 3 open-market purchases and 8 sales; 105 institutions reported holding it in 13F filings for Q2 2026, worth $941.0M in total; no superinvestor holds it.
Key figures
- Insider buysLast 90 days, $65.5M in total
- 3
- Insider sellsLast 90 days, $11.6M in total
- 8
- 13F holdersQ2 2026, +26 vs. previous quarter
- 105
- 13F valueReported value at the end of Q2 2026
- $941.0M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding MPLT, Q2 2026
No superinvestor reported holding MPLT at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by MapLight Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 18, 2026 (view filing)4:15 PM ET | Sep 16 | 2 days | Hanson KristopherGeneral Counsel | SSaleVoting Common Stock | −16.5K | $11.67 | −$192.7K | −10.8%137.0K after | 10b5-1 |
| Aug 18, 2026 (view filing)6:55 PM ET | Aug 14 | 4 days | Catalyst4, Inc.10% Owner | PPurchaseVoting Common Stock | +4.40M | $11.38 | +$50.1M | +21.0%25.3M after | |
| Aug 18, 2026 (view filing)6:55 PM ET | Aug 14 | 4 days | Catalyst4, Inc.10% Owner | PPurchaseVoting Common Stock | +2.93M | $11.38 | +$33.3M | –2.93M after | Derivative |
| Aug 4, 2026 (view filing)8:39 PM ET | Aug 3 | 1 day | Lillie James WoodruffChief Scientific Officer | SSaleVoting Common Stock | −22.1K | $12.54 | −$276.9K | −9.8%202.4K after | 10b5-1 |
| Jul 30, 2026 (view filing)6:39 PM ET | Jul 28-30 | 2 days | Catalyst4, Inc.10% Owner | PPurchaseVoting Common Stock | +1.21M | $12.66 | +$15.3M | +6.1%20.9M after | 4 lots |
| Jul 28, 2026 (view filing)9:14 PM ET | Jul 28 | Same day | Cox TroyDirector | PPurchaseVoting Common Stock | +15.6K | $9.52 | +$148.7K | New position15.6K after | |
| Jul 20, 2026 (view filing)6:00 AM ET | Jul 15-17 | 5 daysLate | Gillis JonathanCAO and Interim CFO | SSaleVoting Common Stock | −37.0K | $37.12 | −$1.37M | −20.4%144.2K after | 7 lots10b5-1 |
| Jul 20, 2026 (view filing)6:00 AM ET | Jul 15-17 | 5 daysLate | Kreitzer AnatolChief Discovery Officer | SSaleVoting Common Stock | −36.3K | $37.09 | −$1.35M | −17.2%174.9K after | 7 lots10b5-1 |
| Jul 17, 2026 (view filing)9:46 PM ET | Jul 15-17 | 2 days | Kroeger Christopher A.Chief Executive Officer | SSaleVoting Common Stock | −147.6K | $36.87 | −$5.44M | −10.6%1.25M after | 7 lots |
| Jul 17, 2026 (view filing)9:45 PM ET | Jul 15-17 | 2 days | Lillie James WoodruffChief Scientific Officer | SSaleVoting Common Stock | −18.3K | $36.88 | −$673.6K | −7.5%224.5K after | 7 lots |
Top 10 13F holders, Q2 2026
The largest institutional positions in MapLight Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Novo Holdings A/S | 3,686,622 | $132.1M | 7.67% | 00.0% | Unchanged |
| FCPM III Services B.V. | 3,226,400 | $115.6M | 15.41% | 00.0% | Unchanged |
| T. Rowe Price Investment Management, Inc. | 2,781,728 | $99.7M | 0.07% | −20,209−0.7% | Reduced |
| Goldman Sachs Group Inc | 1,948,312 | $69.8M | 0.01% | −46,561−2.3% | Reduced |
| Price T Rowe Associates Inc | 1,422,935 | $51.0M | 0.01% | +1,310,227+1,162.5% | Added |
| BlackRock, Inc. | 1,025,134 | $36.7M | 0.00% | −314,597−23.5% | Reduced |
| Nan Fung Group Holdings Ltd | 971,253 | $34.8M | 26.47% | 00.0% | Unchanged |
| 5AM Venture Management, LLC | 950,011 | $34.0M | 11.83% | 00.0% | Unchanged |
| Sanofi | 912,041 | $32.7M | 6.12% | 00.0% | Unchanged |
| State Street Corp | 852,150 | $30.5M | 0.00% | +513,034+151.3% | Added |